From Northwell Health, Zucker School of Medicine at Hofstra/Northwell; CaloAesthetic Plastic Surgery, Division of Plastic Surgery, University of Louisville; Division of Plastic Surgery, University of Kentucky; M. D. Anderson Cancer Center, University of Texas in Houston; Partners in Plastic Surgery; the National Center for Plastic Surgery; and the Dallas Plastic Surgery Institute.
Plast Reconstr Surg. 2021 Apr 1;147(4):808-818. doi: 10.1097/PRS.0000000000007784.
Breast implant removal and replacement has been a common secondary breast procedure in the long-term maintenance of breast augmentation, but more recently growing concerns about silicone-related systemic illness, breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), and changing perceptions of aesthetic beauty have seen breast implant removal without replacement become increasingly requested by patients. Explantation can be challenging, especially when performed with a total capsulectomy. Currently, there is no evidence regarding whether a partial or total capsulectomy has any effect on BIA-ALCL risk mitigation in patients that have textured implants without disease. Total capsulectomy with incomplete resection of a mass can contribute to hyperprogression of BIA-ALCL and death. There have also been cases of BIA-ALCL diagnosed years after removal of the textured device and "total capsulectomy." Therefore, the common practice of simple prophylactic capsulectomy in a textured implant to mitigate future disease has not been established and at the current time should be discouraged. In addition, aesthetic outcomes can be quite variable, and patients should have appropriate preoperative counseling regarding the indications and contraindications for explantation, associated risks, financial implications, and postoperative appearance. The authors review salient aspects related to the planning and management of breast implant removal.
乳房植入物的取出和更换一直是隆胸长期维持的常见二次乳房手术,但最近人们越来越关注与硅胶相关的全身性疾病、乳房植入物相关间变性大细胞淋巴瘤 (BIA-ALCL),以及对审美观念的变化,使得越来越多的患者要求取出乳房植入物而不进行更换。取出假体可能具有挑战性,尤其是在进行全包膜切除术时。目前,对于没有疾病的有纹理植入物的患者,部分或全部包膜切除术是否会影响 BIA-ALCL 风险降低,尚无证据。对于有肿块的不完全切除的全包膜切除术可能会导致 BIA-ALCL 的快速进展和死亡。也有在去除有纹理装置和“全包膜切除术”多年后诊断出 BIA-ALCL 的病例。因此,尚未确定在有纹理植入物中进行简单预防性包膜切除术以减轻未来疾病的常见做法,目前应予以劝阻。此外,美学效果可能会有很大差异,患者应在术前就取出假体的适应证和禁忌证、相关风险、经济影响以及术后外观进行适当咨询。作者回顾了与乳房植入物取出的规划和管理相关的重要方面。